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Background: Mu opioid receptors have previously been shown to be altered in people with affective disorders
who died as a result of suicide. We wished to determine whether these changes were more widespread and
independent of psychiatric diagnoses.
Methods: Mu receptor levels were determined using [3 H]DAMGO binding in BA24 from 51 control subjects;
38 people with schizophrenia (12 suicides); 20 people with major depressive disorder (15 suicides); 13 people with
bipolar disorder (5 suicides) and 9 people who had no history of psychiatric disorders but who died as a result
of suicide. Mu receptor levels were further determined in BA9 and caudate-putamen from 38 people with
schizophrenia and 20 control subjects using [3 H]DAMGO binding and, in all three regions, using Western blots. Data
was analysed using one-way ANOVAs with Bonferroni’s Multiple Comparison Test or, where data either didn’t
approximate to a binomial distribution or the sample size was too small to determine distribution, a Kruskal-Wallis
test with Dunn’s Multiple Comparison Test.
Results: [3 H]DAMGO binding density was lower in people who had died as a result of suicide (p<0.01). People with
schizophrenia who had died as a result of suicide had lower binding than control subjects (p<0.001), whilst people
with bipolar disorder (non- suicide) had higher levels of binding (p<0.05). [3 H]DAMGO binding densities, but not
mu protein levels, were significantly decreased in BA9 from people with schizophrenia who died as a result of
suicide (p<0.01).
Conclusions: Overall these data suggest that mu opioid receptor availability is decreased in the brains of people
with schizophrenia who died as a result of suicide, which would be consistent with increased levels of endogenous
ligands occupying these receptors.Background
Although the dynamics that contribute to a person dying
by suicide are multifactorial, highly complex and vary be-
tween individuals [1], studies consistently suggest that
psychiatric disorders confer an increased risk of suicide.
For example, a Danish study found that nearly 50% of
people who died as a result of suicide either had been or
were psychiatric inpatients [2]. A retrospective study in
Hong Kong discovered that 80% of the people who died* Correspondence: elscarr@unimelb.edu.au
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reproduction in any medium, provided the orby suicide had a psychiatric disorder, with 29% of these
having a co-morbid diagnosis [3]. This study also showed
the highest risk of suicide was in people with mood dis-
orders (50%), with suicides in psychotic disorders show-
ing a gender difference (females: 35.1%; males: 19.8%).
Most significantly, the study showed that a psychiatric
diagnosis had an adjusted odds ratio of 28.67 for risk of
suicide.
The concept that psychiatric disorders significantly
increase the risk of suicide is highlighted by a systematic
literature review which showed that, of all factors stud-
ied, psychiatric disorders had the strongest association
with suicide (all psychiatric disorders 91%; of which
mood disorders accounted for 55% and co-morbid diag-
noses 44%) [4]. A recent meta-analysis, which used datad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported that the relative risk of suicide that could be
attributed to any psychiatric disorder was 7.5% for males
and 11.7% for females [5]. Together, these data demon-
strate that there is an urgent need to understand the
drives to suicidal tendencies in people with psychiatric
illnesses; the ultimate goals of such investigations being
to identify markers for such tendencies and/or to
develop interventions to reduce this behaviour.
There is now a body of literature which supports the
hypothesis that neurochemical changes in the brain are
associated with suicidal behaviour, which include roles
for the central serotonergic system [6], the signal trans-
ducer protein kinase C [7] and the glutamatergic system
[8]. There are also studies linking the endogenous opioi-
dergic system to the major psychiatric disorders [9,10]
and suicide [11]. In the case of the mu opioid receptor
(OPRM), it has been reported that these receptors are
increased in the inferior frontal, cingulate, postcentral,
medial temporal and lateral occipitotemporal gyri as well
as the thalamus [12] of young (<41 years) people who
had died as a result of suicide. OPRM were also reported
to be increased in the frontal cortex and caudate [13]
from people who had died as a result of suicide com-
pared to those from age and sex matched control sub-
jects. Significantly, one of these studies [12] only
included people with depression among those who had
died by suicide, whilst the second study predominantly
consisted of people with undetermined diagnoses or
depression (one subject had schizophrenia) [13]. Thus, it
is not clear if there is an interaction between psychiatric
disorder and OPRM in people who died by suicide.
Finally, in a study that did not assign psychiatric diag-
noses to the cohorts, it has been reported that OPRM in
the prefrontal cortex from people who died by suicide
bound agonists with a higher affinity than that for people
who did not die by suicide. However, a decreased binding
affinity was reported for the pre- and post-central gyri
from people who died as a result of suicide [14].
Given the potential for changes in OPRM to be import-
ant in the predisposition of an individual to attempt suicide
and the relative paucity of studies on OPRM, we decided to
measure the density of OPRM using [3H][D-Ala2, N-
MePhe4, Gly-ol]-enkephalin (DAMGO) binding in BA24
from people with no history of psychiatric disorders (con-
trols), people who had died by suicide and had no discern-
able history of psychiatric disorders (suicides) and people
with schizophrenia, major depressive disorder (MDD) or
bipolar disorder (BP); some of whom had died by suicide.
Following our initial studies we went on to measure
[3H]DAMGO binding in BA 9 and the caudate-putamen
(CPu) from people with schizophrenia who had or had
not died as a result of suicide and compared these data
to those from age/sex matched controls (non-suicides) tobegin to determine the extent of altered OPRM binding
in these people. Finally, to determine if changes in radi-
oligand binding were associated with changes in levels of
OPRM protein, we used Western blotting and an anti-
human OPRM antibody to measure protein levels in
BA9, 24 and the caudate from the schizophrenia study
cohorts.
Methods
Approval for this study was obtained from the Ethics
Committee of the Victorian Institute of Forensic Medi-
cine and the Mental Health Research and Ethics Com-
mittee of Melbourne Health (MHREC 2001.613). In all
cases, tissue was obtained, post-mortem, after receiving
written consent from the closest identifiable next-of kin.
In compliance with State laws of the day, the source of
the tissue collected up to 1999 was de-identified on com-
pletion of the case history review, tissue collected after
2002 was not de-identified. Tissues were provided by the
Victorian Brain Bank Network as coded samples so that
investigators cannot identify the donor.
Diagnostic evaluation
Case history reviews were conducted using the Diagnos-
tic Instrument for Brain Studies (DIBS) [15,16], with a
psychologist and psychiatrist reaching a diagnostic con-
sensus using DSM-IV criteria [17]. The inter-rater reli-
ability of this instrument is 94% (mean kappa = 0.88; 95%
confidence interval = 0.7 – 1.0) [18]. Following the re-
view, duration of illness (DOI: time from first contact
with psychiatric services to death) was calculated and lat-
est prescribed doses of psychoactive drugs converted to
standardised drug doses [19] (Additional file 1: Table S1).
Importantly, CNS tissue was collected from cadavers
refrigerated within 5 hours of being found, this has been
shown to markedly slow autolysis processes and protein
degradation [20]. The average time from discovery to aut-
opsy was approximately 36 hours. To ensure preservation
of the CNS molecular cytoarchitecture, samples were
processed using a standardised procedure and rapidly
frozen to −70°C after removal at autopsy [21]. In cases
where death was witnessed, the post-mortem interval
(PMI) was the time between death and autopsy. Where
death was not witnessed, PMI was calculated as the inter-
val mid-way between the donor last being seen alive and
being found dead. Central pH was determined as
described previously [22]; this being recognised as a good
indicator of tissue and protein preservation [23].
Cohort selection and tissue processing
Blocks of BA24 (ventral anterior cingulate gyrus, around
the genu of the corpus callosum) were removed from the
brains of 51 controls, 38 people with a diagnosis of
schizophrenia (12 suicides), 20 people with a diagnosis of
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(5 suicides) and 9 suicides with no discernible history of
a psychiatric disorder (see Table 1 for cohort summary
and Additional file 1: Table S1 for details).
Blocks of BA9 (lateral surface of the frontal lobe,
including the middle frontal gyrus superior to the infer-
ior frontal sulcus) and the CPu were excised from the
brains of the 36 people (11 suicides) with schizophrenia
(tissue unavailable from 2 people) and 20 control age
and sex subjects.
The radioligand binding assays were conducted as
single point saturation studies [24], which gives a good
estimate of total available binding sites. Importantly, the
concentration of radioligand used was sufficiently high to
overcome the minor changes in radioligand binding
affinity that occurs in human CNS tissue [25] ensuring
this approach gives a good estimation of total binding
sites within the tissue [26]. Thus, 5x 20 μm sections
(3 total binding; TB, 2 non-specific binding; NS) were cut
from each tissue block using a cryomicrotome (CM1800,
Leica Microsystems) and thaw mounted onto gelatinised
microscope slides. Approximately 100 mg of gray matter
for use in Western blots was excised from the slices these
sections were taken from and stored at −80°C.Radioligand binding
[3H]DAMGO binding (3.3 x10-9 M) was measured in
the presence (NS) and absence (TB) of 10-6 M naloxone;
adapted from previous studies [12,27]. Sections were
incubated in 50 x10-3 M Tris–HCl, pH7.4, for 1 hour.
After incubation, sections were washed in ice-cold assay
buffer, dipped in ice-cold water and thoroughly dried
prior to being desiccated overnight in paraformaldehyde
fumes. The sections, alongside [3H]micro-scales™, were
apposed to BAS-TR2025 imaging plates (14 days), which
were scanned using a BAS5000 high resolution phos-
phoimager. The phosphoimage intensities were mea-
sured by comparison to the intensity of segments onTable 1 A summary of the demographic and collection
data (mean± SEM) for the cohort used in the








Controls 51 52.90 ± 2.62 43.73 ± 2.34 6.280 ± 0.036
Suicides 9 44.56 ± 5.93 33.69 ± 3.67 6.427 ± 0.066
MDD 5 65.00 ± 8.79 34.70 ± 4.34 6.266 ± 0.103
MDD (suicide) 15 50.93 ± 4.69 39.45 ± 3.69 6.572 ± 0.053
BP 8 67.25 ± 2.827 36.03 ± 6.688 6.269 ± 0.072
BP (suicide) 5 41.40 ± 4.214 32.10 ± 4.173 6.348 ± 0.074
Schizophrenia 26 54.38 ± 2.619 38.07 ± 2.395 6.190 ± 0.052
Schizophrenia
(suicide)
12 29.25 ± 2.769 44.67 ± 4.030 6.261 ± 0.043[3H]microscales™ using AIS image analysis software.
Results were expressed as specific binding (TB minus
NS) in dpm/mg estimated wet weight tissue equivalents
(ETE) and converted to fmol/mg ETE [26].
Western blots
Homogenates were prepared from CNS tissue, at 5% w/v,
in 10 x10-3 M Tris, (pH 7.4), containing 1% sodium
dodecylsulphate and 1 x10-3 M fresh sodium orthovana-
date and diluted in reducing buffer to give final protein
concentrations of 1.0 mg/ml. Optimisation experiments
showed that different protein concentrations from each
region were within the linear range of the detection sys-
tem. Thus the total protein loaded was; BA 9: 30 μg, BA
24: 10 μg and caudate: 40 μg. The proteins in each
sample (run in duplicate) were separated using polyacryl-
amide gel electrophoresis (4% stacking gel, 10% running
gel). They were transferred to nitrocellulose membranes
overnight in Towbin transfer buffer [28]. Equal protein
loading and transfer was confirmed by staining with 0.1%
ponceau S in 3% trichloroacetic acid. Membranes were
blocked for an hour at room temperature in Tris buffered
saline with 1% Tween 20 (TTBS) and incubated with
rabbit anti-OPRM antibody (1/2000 in TTBS) overnight
at 4°C. This was followed by incubation with goat anti-
rabbit antibody conjugated to horseradish peroxidise
(1/2000 in TTBS) for an hour at room temperature. The
antigenic reaction was visualised using enhanced chemi-
luminescence (ECL) and imaged using a Kodak Image
Station 440CF. The sum intensity of the antigenic bands
was measured using Kodak 1D software.
To control for inter-blot variability, an internal control
(IC) sample [29], was run (in duplicate) on every gel,
which were imaged so that the sum intensity of the
IC fell within a previously established range. The sum
intensities of all samples were standardised as a ratio of
Internal Control (ratio IC).
Statistics
All data sets were analysed using the D’Agostino &
Pearson omnibus normality test to determine whether
they approximated to Gaussian distribution. If the data
was normally distributed, a Grubb’s test was used to de-
termine the presence of outliers. Due to small sample
sizes, age, PMI and brain pH for the groups were com-
pared using a Kruskal-Wallis test with Dunn’s Multiple
Comparison Test. Pearson product–moment correla-
tions, assuming a straight line fit, were used to determine if
there was a relationship between these factors and experi-
mental data. Interpretation of Pearson product–moment
correlations was assisted by published guidelines [30]; with
an r value of 0.3 (r2 = 0.09) deemed to describe a typical re-
lationship and a value of 0.5 (r2 = 0.25) describing a substan-
tial relationship.
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tors on the experimental data was determined by analysis
of covariance (ANCOVA). For the radioligand binding
data, a Student’s unpaired t-test was used to determine
whether there were changes in binding density with sui-
cide. Due to the small samples sizes for some groups, a
Kruskal-Wallis test with Dunn’s Multiple Comparison
Test, or a general linear model (GLM) which is most
suitable for dealing with complex data sets were
employed to identify variations in binding density be-
tween groups. Finally, in the schizophrenia/control co-
hort, one-way ANOVAs with Bonferroni’s Multiple
Comparison Test were used to identify variations in
[3H]DAMGO binding and OPRM protein levels between
groups in each CNS region. GLMs and ANCOVAs were
conducted using Minitab (Release 13.31, www.minitab.
com); all other statistical analyses were carried out using
Graphpad Prism (version 5.04 for Windows, Graphpad
Software, San Diego, California, USA).Results
Demographic and tissue collection data
The final recorded antipsychotic dose (chlorpromazine
equivalents) and duration of illness in the people with
schizophrenia were the only collection-related variables
not normally distributed. There were significant variances
associated with age (Kruskal-Wallis statistic = 30.80,
p<0.0001) and pH (Kruskal-Wallis statistic = 27.87,
p<0.001), but not PMI (Kruskal-Wallis statistic = 9.24,
p = 0.24) between the groups. Post-hoc Dunns Multiple
Comparison test revealed that the variance with age
was due to the schizophrenia _ suicide group being
younger than the control (p<0.01), MDD_non_suicide
(p<0.05), BP_non_suicide (p<0.001) and the schizophre-
nia_non_suicide groups (p<0.01; Additional file 2: Table
S2). Using the same approach, the variance with brain
pH was found to be due to the tissue from the
MDD_suicide group being higher than for the control
(p<0.01) and schizophrenia_suicide (p<0.01) and schizo-
phrenia_non_suicide (p<0.001) groups (Additional file 2:
Table S2).[3 H]DAMGO Binding in BA24 and suicide
[3H]DAMGO binding was homogenous across BA24
(see Figure 1a) therefore an integrated measure was
taken across all cortical laminae. [3 H]DAMGO binding
from people who had or had not died from suicide
approximated to a Gaussian distribution and a Grubbs
test revealed no outlying data. Significantly, there was a
16% decrease in the density of radioligand binding to
OPRM in BA24 from people who had died by suicide
(n = 41) compared to those who had not died by suicide
(n = 81, p = 0.008, see Table 2 and Figure 1b).[3 H]DAMGO Binding in BA24, suicide and psychiatric
diagnoses
To determine if the changes in OPRM in BA24 showed
any suicide x psychiatric diagnosis, we divided the data
according to suicide status within each clinical diagnoses.
This showed changes in [3H]DAMGO binding varied
with suicide status (F7,114 = 4.16, p = 0.0004) and was due
to a 34% increase in binding in the BP_non_suicide
group and a 33% decrease in the schizophrenia _ suicide
group (see Table 2 and Figure 1c).Potential confounds
There were substantial correlations between [3H]
DAMGO binding and age in controls, MDD_non_suicide,
MDD_suicide, BP_non_suicide and schizophrenia_suicide
as well as between binding and pH in MDD and
BP_suicide (Additional file 2: Table S2). Furthermore,
when [3H]DAMGO binding was analysed with age and
pH as cofactors, age (F1,89 = 23.12, p<0.0001) and pH
(F1,89 = 3.91, p = 0.05) were shown to contribute to the vari-
ance associated with the binding data. However, even tak-
ing these factors into account, the suicide x psychiatric
diagnoses differences were still strongly significant
(F7,89 = 2.93, p = 0.008).Mu opioid receptors and suicide in schizophrenia
[3 H]DAMGO binding
Whilst the primary focus of this study was the potential
interactions between diagnoses x suicide, a sub-analyses
of the BA 24 data revealed that there was a 33% decrease
in binding in the schizophrenia_suicide group compared
to the schizophrenia_non_suicide group (Table 2),
prompting further study of the potential interactions
between suicide x schizophrenia in other CNS regions.
Subsequently, we measured [3H]DAMGO binding in
BA9 (Figure 2a) and CPu (Figure 2b) from people
with schizophrenia_ suicide, schizophrenia_non_suicide
and age matched controls only. These data were shown
to approximate to a Gaussian distribution in both regions
and Grubbs test revealed one outlier in the data in the
CPu from people with schizophrenia (Z >2.82). For trans-
parency, analyses are presented with and without that
outlier. With the outlier, there was a significant variation
in [3H]DAMGO binding in the CPu with diagnoses
(With outlier: F2,53 = 3.90, p = 0.026; without outlier:
F2,52 = 4.66, p = 0.013). Binding in the schizophrenia _ sui-
cide group was decreased by 36% compared to controls
and 31% compared to schizophrenia_non_suicide
(Table 2, Figure 2c).
[3H]DAMGO binding also varied with diagnoses in BA9
(F2,55 = 6.81, p=0.0023), due to a 24% decrease in binding
in the schizophrenia_suicide group compared to controls
and 30% compared to schizophrenia_non_suicide (Table 2,
Figure 1 a) Representative autoradiograph of total [3 H]DAMGO binding in BA24. Insert shows non-specific binding. Results for the
radioligand are represented graphically (mean± SEM, fmole/mg ETE): b) Effect of suicide per se on levels of [3 H]DAMGO binding in BA24. c) Effect
of psychiatric disorder and suicide on levels of [3 H]DAMGO binding in BA24.
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the schizophrenia_non_suicide differ from that in controls.Potential confounds
Pearson product–moment correlations indicated that
age, pH and DOI but not PMI or chlorpromazine
equivalents, had significant associations with [3H]
DAMGO binding (Additional file 2: Table S2). Signifi-
cantly, reanalysing the schizophrenia cohort data with
age and pH as covariates showed that although age
(F1,161 = 25.48, p<0.0001) and pH (F1,161 = 5.64, p = 0.019)
contributed to the variance in binding, the variation
associated with suicide was still significant (F2,161 = 3.33,
p = 0.038).OPRM protein
The antigenic band measured in these studies had the
predicted molecular weight for MOR and, in our hands,
showed the expected rank order of intensity (reflecting
OPRM levels) across different brain regions (i.e. thal-
amus > cortex > caudate; data not shown) [12,27]) and
was present in thalamic membrane and cytosolic [31-33]
but not nuclear fractions (Figure 3a).
OPRM data showed a Gaussian distribution with
no outliers. There was no variance in OPRM protein
levels between diagnostic groups in any region (BA9:
F2,55 = 0.644, p = 0.53; BA24: F2,55 = 0.953, p = 0.392; caud-
ate: F2,53 = 1.22, p = 0.303; see Figure 3b).Overall, there were no correlations between age, pH,
DOI or chlorpromazine equivalents and OPRM levels
(Additional file 2: Table S2). However, there were sub-
stantive relationships between OPRM level and age
(r2 = 0.4809) and pH (r2 = 0.3758) in BA9 from the
schizophrenia_ suicide group. An ANCOVA revealed
that neither age (F1,53 = 0.67, p = 0.417) nor pH
(F1,53 = 2.12, p = 0.151) had a significant effect on OPRM
levels in BA 9. Furthermore, taking these 2 factors into
account did not affect the outcome of the analysis
(F2,53 = 0.72, p = 0.49).
Discussion
This study has shown decreased [3H]DAMGO binding
in BA24, BA9 and the CPu from people with schizophre-
nia who died by suicide which, in BA24, was first
revealed as a significant decrease in [3H]DAMGO bind-
ing in larger cohort where people who had died by sui-
cide were compared to those who had not. Significantly
there were no differences in [3H]DAMGO binding in
BA 24 from people with either MDD or BP who had
died as a result of suicide, making this a specific associ-
ation with suicide in schizophrenia. However, this study
did show an increase in [3H]DAMGO binding in BA24
from people with BP who did not died by suicide. Some
caution is needed in the interpretation of this finding in
BP because of the relatively small number of individuals
making up this cohort, particularly given that lithium
treatment has been shown to increase OPRM expression
Table 2 Levels of [3 H]DAMGO (mean± SEM) binding in subjects with schizophrenia, major depressive disorder, bipolar
disorder or no history of psychiatric disorder who did or did not die as a result of suicide




Analysis parameters P value
Suicide 41 32.25 ± 1.76 t = 2.7, df = 120 (non-suicide) 0.008
Non-suicide 81 38.34 ± 1.34
Diagnosis/suicide BA 24
Controls 51 37.63 ± 1.83
Suicides 9 34.02 ± 3.80 t = 0.88 (controls) n.s
MDD 5 27.95 ± 9.06 t = 1.84 (controls) n.s
MDD (suicide) 15 35.69 ± 2.84 t = 0.58 (controls) n.s
BP 8 50.51 ± 1.98 t = 3.00 (controls) n.s
BP (suicide) 5 35.38 ± 3.07 t = 0.43 (controls) n.s
Schizophrenia 26 37.80 ± 1.83 t = 0.04 (controls) n.s
Schizophrenia (suicide) 12 25.31 ± 3.17 t = 3.39 (controls) t = 3.21 (schizophrenia) <0.05
Schizophrenia/suicide BA 9
Controls 20 31.65 ± 2.11
Schizophrenia 26 34.40 ± 1.32 t = 1.15 (controls) n.s
Schizophrenia (suicide) 12 24.12 ± 2.27 t = 2.57 (controls) t = 3.68 (schizophrenia) <0.05 <0.05
CPu
Controls 20 25.40 ± 2.16
Schizophrenia 24 23.72 ± 1.37 t = 0.67 (controls) n.s
Schizophrenia (suicide) 11 16.29 ± 2.42 t = 2.97 (controls) t = 2.50 (schizophrenia) <0.05 <0.05
The group comparison the analysis factors refer to is given in brackets below the parameters. Abbreviations: n.s. = not significant.
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investigation, it was not pursued in this study as it was
not central to investigating the interactions between sui-
cide x psychiatric disease.
Our study showed that [3H]DAMGO binding
increased with age, replicating previous studies that have
reported this relationship [12,13]. Significantly, although
DAMGO binds to all OPRM splice variants with similar
affinities [35] our data showed that levels of OPRM pro-
tein did not vary with age. Thus, our data is the first to
indicate that the number of available [3H]DAMGO bind-
ing sites increases with age in the absence of changes in
levels of OPRM, which would be consistent with
decreasing levels of endogenous ligand occupancy with
age. This hypothesis is supported from previous data on
endogenous opioids in rat CNS [36] and in pain respon-
siveness in humans [37]. Together, these data suggest
levels of endogenous opioid ligands decrease with age.
We have shown that decreased [3H]DAMGO binding
is detectable across several CNS regions in people with
schizophrenia who died as a result of suicide, even
when the effects of confounding factors such as age and
tissue pH are taken into account, with no difference in
binding levels between controls and people with schizo-
phrenia. Our data partly replicates a previous study that
showed no changes in binding to OPRM in people with
schizophrenia who “had died from. . ... natural causes”[38] but contrasts with another report showing
decreased binding to OPRM in the caudate from people
with the disorder [39]. The latter study used tissue from
people who had died as a result of either suicide or
pneumonia but did not explore whether there was an
association between low levels of binding and suicide;
thus, it is possible that the decrease reported was due
to suicide. However, our finding of low [3H]DAMGO
binding density in suicide per se does not agree with
previous studies which report increased OPRM binding
in the inferior frontal, cingulate, postcentral, medial
temporal and lateral occiptotemporal gyri as well as the
thalamus of young suicides [12] and in the frontal cor-
tex and caudate [13] from people who had died by sui-
cide or unaltered levels of radioligand binding in
prefrontal cortex and prepost central gyri from people
who suicided [14]. Notably, in the earliest studies inves-
tigating suicide and OPRM, tissue was obtained from
individuals who had died by suicide and predominantly
had MDD or BP; thus, these data are in contrast with
our findings of no difference in levels of OPRM binding
in people with MDD or BP who had died by suicide. By
contrast, our finding of no change in [3H]DAMGO
binding in people with mood disorders or no history of
psychiatric illness who had died by suicide is consistent
with a previous study [14], which did not report on psy-
chiatric diagnoses.
Figure 2 Representative autoradiographs of total [3 H]DAMGO binding in a) BA9 and b) caudate-putamen; inserts show non-specific
binding. c) Effect of suicide on radioligand binding in these areas are represented graphically (mean± SEM, fmole/mg ETE).
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binding with no changes in OPRM protein would be
consistent with a change in receptor availability rather
than receptor number. There are three scenarios that
would account for this decrease in agonist binding with-
out a change in overall levels of protein. Firstly, it is pos-
sible that there is a change in the confirmation of the
receptor which affects the binding of the ligand. Sec-
ondly, the biochemical modifications that are required
for the insertion of the receptor into the membrane
could be aberrant, reducing the availability of the recep-
tor but not affecting the overall number of receptors.
Finally, the simplest explanation is that the decrease in
binding is due to competition for the binding site be-
tween the radioligand and an endogenous ligand. The
latter hypothesis has been argued previously in the re-
port of altered affinity for [3 H]DAMGO in tissue from
people who died as a result of suicide [14] as changes in
binding affinities are usually due to competition from
endogenous ligands [40,41]. More recently, a positron
emission tomography (PET) study reported that people
with high impulsivity scores released higher levels of
endogenous opioids in response to stress [42], resulting in
lower [11C]carfentanil non-displacable binding potential.
Impulsivity has been proposed as a candidate endophe-
notype for suicidal behaviour [43]; thus, it is possible the
decreased OPRM availability in people with schizophre-
nia who died by suicide is due to increased endogenousopioid levels in response to external stressors. Two such
molecules, endomorphin 1 and endomorphin 2, have
high affinities and selectivity for OPRM (see [44]) making
them prime candidates for future studies.
As with most approaches to the study of the neurobiology
of psychiatric disorders, this study has some potentially con-
founding factors. In particular, we and others [12,13] have
shown that [3H]DAMGO binding increases with age. In
our study the changes in [3H]DAMGO binding remained
when the effect of age was taken into account using an
ANCOVA. Another confound is that all people with psychi-
atric disorders received psychotropic drugs prior to death.
Overall, the literature suggests that treatment of rodents
with antipsychotics results in either a decrease in the levels
of OPRM [45,46] or no change [47] although clozapine,
which none of the subjects with schizophrenia received (see
Additional file 1: Table S1 for details), has been reported to
cause decreases [48]. Evidence against the change in [3H]
DAMGO binding in tissue from people with schizophrenia
who died by suicide being related simply to the effects of
antipsychotic drugs are i) people with schizophrenia who
did or did not die by suicide had been treated with anti-
psychotic drugs, receiving similar levels of final recorded
drug doses expressed as chlorpromazine equivalents (Mann
Whitney U=131.0, medians: schizophrenia_non_suicide=
1216, schizophrenia_suicide=1418;) and the difference in
[3H]DAMGO binding is present in all regions between
these groups, ii) some of the people with BP had received
Figure 3 a) Western blot showing the levels of OPRM in (left to right): Molecular weight standards in lane 1, values given in kDa;
membrane, nuclear and cytosol fractions, in lanes 2–4 respectively. Band measured in subsequent experiments identified by the arrow. b)
Levels of OPRM protein in BA24, 9 and CPu from controls and people with schizophrenia who did or did not die as a result of suicide are
represented graphically (mean± SEM, ratio of internal control).
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in [3H]DAMGO binding in people with this disorder who
had died by suicide compared to control subjects and an in-
crease in the BP_non_suicide group.
One potential methodological confound in our study
was that the cohort size of people with schizophrenia
who died as a result of suicide was relatively small. How-
ever, a power analysis (http://www.biomath.info/power/
ttest.htm) showed our study was appropriately powered
in BA 9 and 24 (power level 0.8) but was underpowered
for the mean differences observed in the CPu (9 add-
itional non-suicide people were needed).
Conclusions
Our study is the first to suggest there is a decrease in the
availability of [3H]DAMGO binding sites in people with
schizophrenia who died by suicide. Given the strong link
between schizophrenia and the inclination to complete sui-
cide [49], further studies to understand the consequences
of changes in the opioid system and its relationship to
suicide in schizophrenia are warranted. It is possiblethat these chemical changes, if detectable by neuroimaging
or by a peripheral measure, could be used clinically to
identify people with a disposition to suicide which would
facilitate the implementation of appropriate interventions
[50]. Similarly, our novel, preliminary data on increased
[3H]DAMGO binding in BP are intriguing and deserve
further investigations. Both findings add to the long held
argument that the opioid system plays an important role
in the pathophysiology and/or outcomes of psychiatric
disorders [51].
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